Gliolan is named as an intervention in 3 current clinical trials in our China, Germany and France registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Lee's Pharmaceutical Limited (1). The most-studied condition is 5-aminolevulinic Acid. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)
NCT06160492 · ClinicalTrials.gov ↗ · 5-aminolevulinic Acid, Fluorescence-guided Resection
|
Phase 3 | Recruiting | Lee's Pharmaceutical Limited | China |
|
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
NCT05590689 · ClinicalTrials.gov ↗ · Glioblastoma
|
Phase 1/2 | Recruiting | Universität Münster | Germany |
|
Fluorescence Guided Focal Cortical Dysplasia Surgery
NCT07657975 · ClinicalTrials.gov ↗ · Drug Resistant Epilepsy
|
Phase 2 | Not yet open | Hospices Civils de Lyon | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Gliolan. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Evaluation of the efficacy and safety of photodynamic therapy with BF-200 ALA (Ameluz®) in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma at any location.
2026-526649-85-00 · Skin and Connective Tissue Diseases
|
Phase 3 | Authorised | Dra. Elena González Guerra | Spain |
| Lead sponsor | Trials |
|---|---|
| Lee's Pharmaceutical Limited | 1 |
| Universität Münster | 1 |
| Hospices Civils de Lyon | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in France | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
3 current trials in our China, Germany and France registers name Gliolan (also registered as 5-aminolevulinic acid) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in China and 1 with sites in Germany. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Lee's Pharmaceutical Limited (1), Universität Münster (1) and Hospices Civils de Lyon (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gliolan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gliolan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gliolan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.